{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:17:12Z","timestamp":1787847432025,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T00:00:00Z","timestamp":1623542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>We previously described a risk prediction model (Anne Arundel Medical Center [AAMC] model) based on pathology which may eliminate the need for recurrence score (RS) testing in select early-stage breast cancers. There is a concern that patients in discordant risk prediction groups (AAMC vs. RS) may be overtreated or undertreated if RS testing were omitted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We queried the Surveillance, Epidemiology, and End Results (SEER) database for all breast cancer patients between 2004 and 2015. AAMC low-risk was defined as Grade 1 and progesterone receptor-positive (PR +) tumors, while AAMC high-risk was defined as Grade 3 or estrogen-negative tumors. RS low-risk group was defined as RS &lt; 16 and age \u2264 50 years, or RS \u2264 25 and age &gt; 50 years. RS high-risk group was defined as RS &gt; 25.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 71,212 cases were analyzed. Of these, 590 were AAMC low-risk\/RS high-risk discordant, while 5,596 were AAMC high-risk\/RS low-risk discordant. For AAMC low-risk\/RS high-risk discordant, 10-year breast cancer- specific survival (BCSS) did not differ for patients who received adjuvant chemotherapy versus those who did not (93% chemotherapy vs. 99% unknown\/no chemotherapy,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .12). Overall survival (OS) was also comparable (92% chemotherapy vs. 91% unknown\/no chemotherapy,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .42). In the AAMC high-risk\/RS low-risk discordant group, 10-year BCSS (92% chemotherapy vs. 96% unknown\/no chemotherapy,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .06) and OS (87% chemotherapy vs. 90% unknown\/no chemotherapy,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .52) did not differ between adjuvant chemotherapy and unknown\/no chemotherapy groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Adjuvant chemotherapy in the AAMC low-risk\/RS high-risk and AAMC high-risk\/RS low-risk discordant groups did not improve survival. This supports consideration of omission of RS testing in Grade 1, PR + tumors. Patients with Grade 3 tumors do benefit from RS testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2021.05.005","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T05:52:36Z","timestamp":1623909156000},"page":"44-51","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Recurrence Score Testing Does not Appear to Benefit Patients With Grade 1, Progesterone Receptor-Positive Breast Cancers"],"prefix":"10.4103","volume":"15","author":[{"given":"Udai S.","family":"Sibia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Mylander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Tweed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Tafra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubie S.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20241211","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-7-20241211","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-7-20241211","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"R5-7-20241211","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.clbc.2015.04.006","article-title":"A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay","volume":"15","author":"Gage","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"R6-7-20241211","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2016.67.7195","article-title":"Optimizing the use of gene expression profiling in early-stage breast cancer","volume":"34","author":"Kim","year":"2016","journal-title":"J Clin Oncol"},{"key":"R7-7-20241211","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdy074","article-title":"Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay","volume":"29","author":"Gage","year":"2018","journal-title":"Ann Oncol"},{"key":"R10-7-20241211","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3332\/ecancer.2020.1007","article-title":"Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer","volume":"14","author":"Binotto","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"R11-7-20241211","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jgo.2017.10.001","article-title":"The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged \u226570 with early stage invasive breast cancer","volume":"9","author":"Quinten","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"R12-7-20241211","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-9966-27-32","article-title":"Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007","volume":"27","author":"Montazeri","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"key":"R13-7-20241211","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: Agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J Clin Oncol"},{"key":"R14-7-20241211","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1200\/JCO.2016.68.4480","article-title":"Obesity and breast cancer prognosis: evidence, challenges, and opportunities","volume":"34","author":"Jiralerspong","year":"2016","journal-title":"J Clin Oncol"},{"key":"R15-7-20241211","first-page":"675","article-title":"Weight gain and quality of life in women treated with adjuvant chemotherapy for early-stage breast cancer","volume":"28","author":"McInnes","year":"2001","journal-title":"Oncol Nurs Forum"},{"key":"R17-7-20241211","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1200\/JOP.18.00796","article-title":"Financial costs and burden related to decisions for breast cancer surgery","volume":"15","author":"Greenup","year":"2019","journal-title":"J Oncol Pract"},{"key":"R18-7-20241211","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00520-018-4418-4","article-title":"\u201cIt still affects our economic situation\u201d: long-term economic burden of breast cancer and lymphedema","volume":"27","author":"Dean","year":"2019","journal-title":"Support Care Cancer"},{"key":"R19-7-20241211","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/13696998.2016.1192548","article-title":"Adverse event- related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries","volume":"19","author":"Irwin","year":"2016","journal-title":"J Med Econ"},{"key":"R20-7-20241211","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1634\/theoncologist.2014-0059","article-title":"Investigation of adverse-event- related costs for patients with metastatic breast cancer in a real-world setting","volume":"19","author":"Hurvitz","year":"2014","journal-title":"Oncologist"},{"key":"R21-7-20241211","first-page":"173","article-title":"Economic burden related to chemotherapy- related adverse events in patients with metastatic breast cancer in an integrated health care system","volume":"8","author":"Rashid","year":"2016","journal-title":"Breast Cancer"},{"key":"R22-7-20241211","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient\u2019s experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"key":"R23-7-20241211","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jamaoncol.2016.4850","article-title":"Mitigating financial toxicity among US patients with cancer","volume":"3","author":"de Souza","year":"2017","journal-title":"JAMA Oncol"},{"key":"R24-7-20241211","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.2010.33.3179","article-title":"Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer","volume":"29","author":"Neugut","year":"2011","journal-title":"J Clin Oncol"},{"key":"R25-7-20241211","doi-asserted-by":"crossref","first-page":"djv410","DOI":"10.1093\/jnci\/djv410","article-title":"Minimizing the \u201cfinancial toxicity\u201d associated with cancer care: Advancing the research agenda","volume":"108","author":"Tucker-Seeley","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R26-7-20241211","first-page":"149","article-title":"Financial toxicity, Part I: A new name for a growing problem","volume":"27","author":"Zafar","year":"2013","journal-title":"Oncology"},{"key":"R27-7-20241211","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","article-title":"Financial insolvency as a risk factor for early mortality among patients with cancer","volume":"34","author":"Ramsey","year":"2016","journal-title":"J Clin Oncol"},{"key":"R28-7-20241211","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1377\/hlthaff.2012.1263","article-title":"Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis","volume":"32","author":"Ramsey","year":"2013","journal-title":"Health Aff"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S165838762100056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S165838762100056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2021.05.005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:17:59Z","timestamp":1787843879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2021.05.005"}},"subtitle":["An Opportunity to Eliminate Overtreatment and Decrease Testing Costs"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2021.05.005","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}